NEW

Stock Screener with Intrinsic Value

TRY FOR FREE

Alnylam Pharmaceuticals, Inc. (ALNY)

Last Price$238.0(1.1%)

Market Cap$30.1B

LTM Total Debt to Total Equity

40.2x

5Y avg

(42.6x)

Biotechnology industry median

0.0x

Stock quality & Intrinsic value

6/10

(0.6%) overvalued

Start beating the S&P 500

Alnylam Pharmaceuticals, Inc. Total Debt to Total Equity

Annual

Quarterly

LTM

Industry median

Company stand-alone

ALNY

Healthcare

Crunching data... Almost there!

	Dec'04	Dec'05	Dec'06	Dec'07	Dec'08	Dec'09	Dec'10	Dec'11	Dec'12	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Total Debt to Total Equity	0.2x	0.1x	0.0x	0.0x	0.0x	0.0x	0.0x	0.0x	0.0x	0.0x	0.0x	0.0x	0.2x	0.0x	0.0x	0.4x	0.5x	3.7x	(16.5x)	(12.2x)

ALNY

Key metrics and insights to make informed decisions.

View full analysis

Overvalued or undervalued?

Check the intrinsic value for ALNY and see if it's the right time to invest.

Dive in

Alnylam Pharmaceuticals, Inc. (ALNY) Total Debt to Total Equity comparison analysis

Crunching data... Almost there!

ALNY key stats

USD

Millions

Billions

Annual

Quarterly

Trailing

Key stats

Income statement

Balance sheet

Cash Flow Statement

Valuation

Ratios

Per share

Per employee

Dividends & Yields

Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

Loved by
investors
worldwide

10K+

Investors use our platform

Top value investing hub with all necessary tools

1K+

Experienced investors in our community

4.9

Average rating across all rating platforms

Start for free ->

FAQ

1) What is Alnylam Pharmaceuticals, Inc.'s Total Debt to Total Equity?

As of today, Microsoft Corp's last 12-month Total Debt to Total Equity is 40.2x, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Total Debt to Total Equity for Alnylam Pharmaceuticals, Inc. have been (59.8x) over the past three years, and (44.8x) over the past five years.

2) Is Alnylam Pharmaceuticals, Inc.'s Total Debt to Total Equity Good?

As of today, Alnylam Pharmaceuticals, Inc.'s Total Debt to Total Equity is 40.2x, which is higher than industry median of 0.0x. It indicates that Alnylam Pharmaceuticals, Inc.'s Total Debt to Total Equity is Bad.

3) How does Alnylam Pharmaceuticals, Inc.'s Total Debt to Total Equity compare to its peers?

As of today, Alnylam Pharmaceuticals, Inc.'s Total Debt to Total Equity is 40.2x, which is higher than peer median of 0.1x. The list of peers includes NVO, BGNE, MRNA, VRTX, REGN, UTHR, GMAB, BNTX, INCY, ARGX.